Novo Nordisk Will Eat Itself In Obesity
Executive Summary
The Danish diabetes specialist is forging ahead with pivotal trials for its latest GLP-1 offering semaglutide in obesity after highly impressive Phase II efficacy data, but is likely to take the biggest market share from its own product, Saxenda.
You may also be interested in...
Novo Nordisk's Great Hope Semaglutide Shines In Ph II Obesity Study
Highly positive top-line weight loss results for Novo Nordisk's new GLP-1 agonist semaglutide are propelling it into Phase III trials next year for the notoriously tricky indication. The product is currently under review for type 2 diabetes.
10 Clinical Trials To Watch Out For In 2023
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.
Olema Flies Flag For SERDs, Planning Phase III Trials As Rivals Stumble
Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’